PROJECTS WITH INTERNAL FUNDING

ULCER2C; Evaluation of the cost for treating pressure ulcers in cancer patients; PI 173-CI-IPOP 07-2022; 3 527.40 € (2021-2024); Luisa Lopes-Conceição (PI).

Description (2000 caracteres, sem espaços)

The project ULCER2C has the following objectives:
i) To estimate the cost for treating pressure ulcers associated with heath care in hospitalized cancer patients at the Portuguese Oncology Institute of Porto (IPO Porto), using the TDABC method;
ii) To quantify the association between the occurrence of pressure ulcers associated with heath care in hospitalized cancer patients at IPO Porto and the length of inpatient stay.

Costs analysis, effectiveness and safety associated with Chimeric Antigen Receptor-T cell therapy: results from a Portuguese Comprehensive Cancer Center; IPOP-CES 188/020; (2019-2024); Sergio Chacim (PI).

Description (2000 caracteres, sem espaços)

In the population of patients treated with CAR T cells at IPOP, the aims of this project are:
- Assess overall response rate, complete and partial response rate, as well as duration of response
- Evaluate progression-free survival and overall survival
- Assess quality of life during treatment
- Assess toxicities during treatment
- Calculate direct costs associated with treatment
- Compare response rates obtained with CAR T cell treatment with a retrospective cohort of identical characteristics, treated between 2014 – 2018 at IPOP.

Comparison of incidence, survival and healthcare utilization between patients with second primary tumors and patients with only one primary tumor (female breast, prostate, colon and rectal, lung and thyroid cancer); IPOP-CES 50/019; (2019-2024); Filipa Fontes (PI).

Description (2000 caracteres, sem espaços)

The main objectives of this project are to estimate the cumulative incidence of second primary cancers (SPC) in four population-based cohorts of cases with first primary cancer (FPC) of female breast, prostate, colon and rectum, lung and thyroid, followed by for 10 years, according to sociodemographic and FPC characteristics. It is also intended to describe and compare the health care utilization, and costs associated with the health care, of patients with SPC and patients without SPC treated at the IPOP.

FAROL; Implementation of a financing model based on the measurement of clinical and non-clinical outcomes and integrated disease management in lung cancer at IPO Porto; (2018-2023); Marta Soares (PI).

Description (2000 caracteres, sem espaços)

The FAROL project, focused on Health Outcomes and Integrated Disease Management, consists of the development of a funding model centered on measuring results with incentives associated with quality.